Specifically, we found that targeted ablation of Cxcl12 in Il7-Cre+ stromal cells abrogates the tumor-initiating potential of BC cells and that this niche dependence can be therapeutically harnessed through antagonism of CXCR4. The gene discussed is IL7; the disease is breast cancer.